Med Page Today
OCTOBER 29, 2024
(MedPage Today) -- SAN DIEGO -- Semaglutide (Wegovy) reduced albuminuria in patients with overweight or obesity and chronic kidney disease (CKD) but without type 2 diabetes, a randomized trial showed. Among 101 patients, those who received 2.
Medical Xpress - Cardiology
OCTOBER 29, 2024
Until now, patients with aortic stenosis—a narrowing of one of the heart's main valves—have had to wait until symptoms become severe before undergoing valve replacement. Findings from the EVOLVED study, however, indicate that patients can avoid symptoms such as chest pain, dizziness and fainting if surgery is performed at an earlier stage of the condition.
Med Page Today
OCTOBER 29, 2024
(MedPage Today) -- A Chinese study suggested that cold weather may make people more susceptible to myocardial infarction with non-obstructive coronary arteries compared with myocardial infarction from obstructive disease. (European Heart Journal.
Medical Xpress - Cardiology
OCTOBER 29, 2024
A team of researchers have worked together to identify possible genes associated with certain metabolites—molecules involved in the body's biochemical processes—and cardiovascular risk.
Med Page Today
OCTOBER 29, 2024
(MedPage Today) -- The heparin frequently given before percutaneous coronary intervention (PCI) should be pushed to as early as possible in patients with ST-segment elevation myocardial infarction (STEMI), according to findings from the Chinese.
American College of Cardiology
OCTOBER 29, 2024
The goal of the CLEAR SYNERGY OASIS 9 trial was to determine the long-term cardiovascular (CV) effects of colchicine following percutaneous coronary intervention (PCI) for ST-segment elevation or large non–ST-segment elevation myocardial infarction (STEMI or NSTEMI, respectively).
Becker's Hospital Review - Cardiology
OCTOBER 29, 2024
Yale New Haven (Conn.) Health and the Yale School of Medicine have appointed Marc Pelletier, MD, division chief of cardiac surgery for the department of surgery and section chief of cardiac surgery at Yale New Haven Hospital as well as physician-in-chief of cardiac surgery for the health system's Heart and Vascular Center.
Cardiovascular Update brings together the best content for cardiovascular medicine professionals from the widest variety of industry thought leaders.
Cardiovascular Diabetology
OCTOBER 29, 2024
Type 2 diabetes has traditionally been a risk factor for worse prognosis after myocardial infarction (MI), but major advances have been made in its treatment, and the use of secondary preventive measures has i.
HCPLive
OCTOBER 29, 2024
This discussion with Murina covers several tips for dermatologists to implement, 1 of which touched on omega-3 supplementation for ocular rosacea.
DAIC
OCTOBER 29, 2024
tim.hodson Tue, 10/29/2024 - 09:55 Oct. 28, 2024 – Elixir Medical today announced late-breaking data demonstrating significant benefit of the DynamX Coronary Bioadaptor System compared to contemporary Resolute Onyx zotarolimus drug-eluting stent (DES) for target lesion failure (TLF) in complex patient population subsets from the INFINITY-SWEDEHEART RCT.
HCPLive
OCTOBER 29, 2024
A trio of stakeholders join Lungcast to discuss the ongoing, long-term assessment into the patterns and drivers of chronic lung disease in a real-world cohort.
DAIC
OCTOBER 29, 2024
tim.hodson Tue, 10/29/2024 - 11:29 Impella ECP pump insertion. Oct. 28, 2024 — Results from the first completed pivotal trial on patients supported with Impella ECP, a novel transvalvular axial flow pump with compressible pump architecture were presented at Transcatheter Cardiovascular Therapeutics (TCT) 2024 conference in Washington, D.C. Impella ECP is a technology of Abiomed, part of Johnson & Johnson MedTech, and a global leader in heart recovery.
HCPLive
OCTOBER 29, 2024
At AAO 2024, Quan Dong Nguyen, MD, and Jia-Horung Hung, MD, discuss the Phase 2 Neptune trial investigating brepocitinib for active non-infectious uveitis.
Med Page Today
OCTOBER 29, 2024
(MedPage Today) -- SAN DIEGO -- Benefits with empagliflozin (Jardiance) for cardiovascular and renal health linger for about a year after discontinuation, as off-drug follow-up from the EMPA-KIDNEY trial showed. During a median 2 years of post.
HCPLive
OCTOBER 29, 2024
Stein Gold speaks in this interview about the new lebrikizumab (Ebglyss) data presented at the Fall Clinical Dermatology Conference.
DAIC
OCTOBER 29, 2024
tim.hodson Tue, 10/29/2024 - 09:55 Oct. 28, 2024 – Elixir Medical today announced late-breaking data demonstrating significant benefit of the DynamX Coronary Bioadaptor System compared to contemporary Resolute Onyx zotarolimus drug-eluting stent (DES) for target lesion failure (TLF) in complex patient population subsets from the INFINITY-SWEDEHEART RCT.
HCPLive
OCTOBER 29, 2024
Only about 2% of eligible patients with ALD have received a pharmacotherapy for alcohol use disorder—and the prescription takes more than a year to receive.
DAIC
OCTOBER 29, 2024
tim.hodson Tue, 10/29/2024 - 10:14 Oct. 27, 2024 — Investigators from Gifu Heart Center and Fukuoka Sanno Hospital recently presented the results of the physician-initiated PROVISION 1 Study at the Cardiovascular Research Foundation's annual Transcatheter Cardiovascular Therapeutics (TCT) conference in Washington, D.C. The investigators shared the first randomized controlled trial (RCT) of FFRangio outcomes compared to invasive wire-based fractional flow reserve (FFR) has met its primary endpoi
HCPLive
OCTOBER 29, 2024
Axelrad reviews preliminary findings from a study assessing the utility of a new monitoring technology for improving IBD medication adherence and outcomes.
Becker's Hospital Review - Cardiology
OCTOBER 29, 2024
"Discover how addressing women's heart health could lead to a $28 billion annual growth in the U.S. economy by 2040.
HCPLive
OCTOBER 29, 2024
Iyer describes differences between short bowel syndrome and intestinal failure and explains the value of GLP-2 analogs like apraglutide for treatment.
American College of Cardiology
OCTOBER 29, 2024
While the main PROTECTED TAVR trial found no significant differences in stroke rates when cerebral embolic protection (CEP) was used during TAVR compared with TAVR alone, a post hoc analysis of the trial presented during TCT 2024 and simultaneously published in JAMA Cardiology, suggests there may be potential benefits associated with CEP use based on geographic region.
HCPLive
OCTOBER 29, 2024
Mayo explains elafibranor’s benefit for patients with advanced-stage primary biliary cholangitis based on findings from a new ELATIVE analysis.
American College of Cardiology
OCTOBER 29, 2024
The goal of the ECLIPSE trial was to evaluate orbital atherectomy prior to drug-eluting stent (DES) implantation compared with conventional percutaneous coronary intervention (PCI) without atherectomy among patients with calcified coronary lesions.
HCPLive
OCTOBER 29, 2024
Sands reviews long-term phase 3 data from the LUCENT-3 and VIVID-2 extension studies of mirikizumab in UC and CD presented at ACG 2024.
American College of Cardiology
OCTOBER 29, 2024
Sirolimus-coated balloons were noninferior to paclitaxel-coated balloons in terms of safety and efficacy in treating patients with femoropopliteal artery disease, based on findings from the head-to-head.
HCPLive
OCTOBER 29, 2024
Complete, 24-month data from the IGNAZ study were presented at the ASN Kidney Week 2024 Meeting.
American College of Cardiology
OCTOBER 29, 2024
Both acute and long-term colchicine use to treat patients with acute myocardial infarction (MI) did not reduce cardiovascular death, myocardial infarction, stroke or ischemia-driven revascularization.
Medical Xpress - Cardiology
OCTOBER 29, 2024
Findings from the TAVR UNLOAD study found limited benefits of transcatheter aortic valve replacement (TAVR) in the treatment of heart failure (HF) with reduced ejection fraction (HFrEF) and moderate aortic stenosis (AS).
American College of Cardiology
OCTOBER 29, 2024
The routine use of orbital atherectomy did not improve minimal stent area (MSA) or reduce target vessel failure (TVF) at one year compared with conventional balloon angioplasty prior to implantation of a drug-eluting stent (DES) in severely calcified coronary lesions.
HCPLive
OCTOBER 29, 2024
A qualitative / quantitative study shows significant gaps in PBC diagnosis confidence and skill between care providers.
American College of Cardiology
OCTOBER 29, 2024
In women with symptomatic, severe aortic stenosis (AS), TAVR with the balloon-expandable valve was superior to surgical aortic valve replacement in terms of the composite rate of death, stroke and rehospitalization at one-year follow-up, according to a pooled analysis of patient-level data from RHEIA and PARTNER 3 trials presented at TCT 2024.
HCPLive
OCTOBER 29, 2024
The FDA originally issued a CRL requesting additional CMC data in April 2024.
American College of Cardiology
OCTOBER 29, 2024
The goal of the PROTECTED TAVR trial was to evaluate the efficacy of intraprocedural cerebral embolic protection (CEP) in reducing strokes among patients undergoing transfemoral TAVR for aortic stenosis.
HCPLive
OCTOBER 29, 2024
Murina highlighted takeaways from her seminar-in-depth regarding the evolving therapeutic landscape of HS.
Medical Xpress - Cardiology
OCTOBER 29, 2024
A new study published in Frontiers of Medicine focuses on establishing normative values for left ventricular (LV) and left atrial (LA) size and function using three-dimensional echocardiography (3DE) among healthy Han Chinese adults.
The New England Journal of Medicine
OCTOBER 29, 2024
The past two decades have witnessed a renaissance in the evaluation and treatment of patients with valvular heart disease, catalyzed by advances in surgical innovation, transcatheter techniques, and multimodality cardiac imaging. Transcatheter aortic-valve replacement (TAVR) has been accepted as a reasonable alternative to surgical aortic-valve replacement for the treatment of.
Expert insights. Personalized for you.
81 
Let's personalize your content